Biological/Research Material for HIV Vaccine Research

Description:
Offered for licensing is a recombinant attenuated vaccinia virus, MVA, that expresses SIV 239gagpol. The materials can be used for research purposes and in particular in the area of HIV/AIDS vaccines.

Plasmid insertion vector pJH-4, containing the foreign gene SIV 239 GagPol controlled by vaccinia early/late promoter, inserts into del III of attenuated vaccinia MVA virus to make recombinant MVA virus. The resulting recombinant virus made from pJH4, MVA/SIV239gagpol, expresses the SIV 239gagpol gene and thus can be used to conduct vaccine studies in animal models such as Rhesus macaques.

The list of publications shown below demonstrates the usefulness of this biological material in HIV vaccine research.
Patent Information:
For Information, Contact:
Benjamin Hurley
Office of Technology Transfer Center
NIH Technology Transfer
240-669-5092
benjamin.hurley@nih.gov
Inventors:
Linda Wyatt
Bernard Moss
Keywords:
239gagpol
ACXXXX
AXXXXX
DC5XXX
DCXXXX
DXXXXX
EXPRESSES
Gene
MVA/SIV239gagpol
MVNSIV239gagpoi
PJH4
recombinant
RESEARCH MATERIAL
SIV
SIV239gagpol
That
virus
© 2024. All Rights Reserved. Powered by Inteum